JAK inhibitors offer safe, effective ‘patient-centric approach’ to broad range of IMIDs

While FDA- and EU-approved JAK inhibitors have shown comparable efficacy and safety across a spectrum of immune-mediated diseases, more study is required to fully parse the mechanism of action, according to a presenter at the 2020 Interdisciplinary Autoimmune Summit.“The objective is to evaluate the role of JAK-inhibitors within the RA and other immune-mediate inflammatory diseases (IMID) treatment armamentarium,” Vibeke Strand, MD, MACR, FACP, adjunct clinical professor in the division of immunology/rheumatology at Stanford University, said in her presentation. “Also, toRead More

Share on facebook
Share on twitter
Share on linkedin